{"id":1250,"date":"2009-07-29T00:00:00","date_gmt":"2009-07-29T00:00:00","guid":{"rendered":"https:\/\/protherics2.aazzxx.com\/news\/btg-plc-astrazeneca-to-progress-cytofab-into-phase-iib-study\/"},"modified":"2022-09-08T10:04:00","modified_gmt":"2022-09-08T10:04:00","slug":"btg-plc-astrazeneca-to-progress-cytofab-into-phase-iib-study","status":"publish","type":"news","link":"https:\/\/serb.com\/nl\/news\/btg-plc-astrazeneca-to-progress-cytofab-into-phase-iib-study\/","title":{"rendered":"BTG PLC: ASTRAZENECA TO PROGRESS CYTOFAB\u2122 INTO PHASE IIB STUDY"},"content":{"rendered":"<p>BTG plc (LSE: BGC), the specialty pharmaceuticals company, today announces that its partner AstraZeneca has confirmed its intention to progress CytoFab\u2122, an investigational biological medicine under development as a treatment for severe sepsis, into a Phase IIb study.<\/p>\n<p>This decision follows the successful completion by AstraZeneca of a Phase IIa study of CytoFab\u2122 in 70 patients with severe sepsis. The Phase IIa study was designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple intravenous infusions of CytoFab\u2122.<\/p>\n<p>The Phase IIb study in approximately 300 patients with severe sepsis is anticipated to start recruiting in early 2010.<\/p>\n<p>Louise Makin, BTG\u2019s CEO, commented: \u201cWe are encouraged by AstraZeneca\u2019s decision to progress CytoFab\u2122 into a Phase IIb study. We look forward to continuing to work with AstraZeneca to develop CytoFab\u2122 as a potential treatment for severe sepsis, which is responsible for many thousands of deaths each year and remains a significant unmet medical need.\u201d<\/p>\n<p>John Rex, Vice-President for Clinical Infection, AstraZeneca, said: \u201cAstraZeneca is aiming to build a leading franchise in the treatment of infectious diseases through our own research and collaborations such as this partnership with BTG. Sepsis is a serious medical problem and CytoFab\u2122 represents a novel approach to this area of unmet medical need.\u201d<\/p>\n<p><strong>For further information contact:<\/strong><\/p>\n<p>BTG<\/p>\n<p>Andy Burrows,<\/p>\n<p>Director of Investor Relations<br \/>\n+44 (0)20 7575 1741<\/p>\n<p>mobile +44 (0)7990 530605<\/p>\n<p>Rolf Soderstrom, Chief Financial Officer<\/p>\n<p>+44 (0)20 7575 0000<\/p>\n<p>Financial Dynamics<\/p>\n<p>Ben Atwell<\/p>\n<p>+44 (0)20 7831 3113<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BTG plc (LSE: BGC), the specialty pharmaceuticals company, today announces that its partner AstraZeneca has confirmed its intention to progress CytoFab\u2122, an investigational biological medicine under development as a treatment for severe sepsis, into a Phase IIb study. This decision follows the successful completion by AstraZeneca of a Phase IIa study of CytoFab\u2122 in 70 [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","class_list":["post-1250","news","type-news","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BTG PLC: ASTRAZENECA TO PROGRESS CYTOFAB\u2122 INTO PHASE IIB STUDY - SERB Pharmaceuticals<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/serb.com\/nl\/news\/btg-plc-astrazeneca-to-progress-cytofab-into-phase-iib-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BTG PLC: ASTRAZENECA TO PROGRESS CYTOFAB\u2122 INTO PHASE IIB STUDY - SERB Pharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"BTG plc (LSE: BGC), the specialty pharmaceuticals company, today announces that its partner AstraZeneca has confirmed its intention to progress CytoFab\u2122, an investigational biological medicine under development as a treatment for severe sepsis, into a Phase IIb study. This decision follows the successful completion by AstraZeneca of a Phase IIa study of CytoFab\u2122 in 70 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/serb.com\/nl\/news\/btg-plc-astrazeneca-to-progress-cytofab-into-phase-iib-study\/\" \/>\n<meta property=\"og:site_name\" content=\"SERB Pharmaceuticals\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-08T10:04:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/serb.com\\\/nl\\\/news\\\/btg-plc-astrazeneca-to-progress-cytofab-into-phase-iib-study\\\/\",\"url\":\"https:\\\/\\\/serb.com\\\/nl\\\/news\\\/btg-plc-astrazeneca-to-progress-cytofab-into-phase-iib-study\\\/\",\"name\":\"BTG PLC: ASTRAZENECA TO PROGRESS CYTOFAB\u2122 INTO PHASE IIB STUDY - SERB Pharmaceuticals\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/serb.com\\\/nl\\\/#website\"},\"datePublished\":\"2009-07-29T00:00:00+00:00\",\"dateModified\":\"2022-09-08T10:04:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/serb.com\\\/nl\\\/news\\\/btg-plc-astrazeneca-to-progress-cytofab-into-phase-iib-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/serb.com\\\/nl\\\/news\\\/btg-plc-astrazeneca-to-progress-cytofab-into-phase-iib-study\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/serb.com\\\/nl\\\/news\\\/btg-plc-astrazeneca-to-progress-cytofab-into-phase-iib-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/serb.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BTG PLC: ASTRAZENECA TO PROGRESS CYTOFAB\u2122 INTO PHASE IIB STUDY\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/serb.com\\\/nl\\\/#website\",\"url\":\"https:\\\/\\\/serb.com\\\/nl\\\/\",\"name\":\"SERB Pharmaceuticals\",\"description\":\"SERB Pharmaceuticals\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/serb.com\\\/nl\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BTG PLC: ASTRAZENECA TO PROGRESS CYTOFAB\u2122 INTO PHASE IIB STUDY - SERB Pharmaceuticals","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/serb.com\/nl\/news\/btg-plc-astrazeneca-to-progress-cytofab-into-phase-iib-study\/","og_locale":"en_US","og_type":"article","og_title":"BTG PLC: ASTRAZENECA TO PROGRESS CYTOFAB\u2122 INTO PHASE IIB STUDY - SERB Pharmaceuticals","og_description":"BTG plc (LSE: BGC), the specialty pharmaceuticals company, today announces that its partner AstraZeneca has confirmed its intention to progress CytoFab\u2122, an investigational biological medicine under development as a treatment for severe sepsis, into a Phase IIb study. This decision follows the successful completion by AstraZeneca of a Phase IIa study of CytoFab\u2122 in 70 [&hellip;]","og_url":"https:\/\/serb.com\/nl\/news\/btg-plc-astrazeneca-to-progress-cytofab-into-phase-iib-study\/","og_site_name":"SERB Pharmaceuticals","article_modified_time":"2022-09-08T10:04:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/serb.com\/nl\/news\/btg-plc-astrazeneca-to-progress-cytofab-into-phase-iib-study\/","url":"https:\/\/serb.com\/nl\/news\/btg-plc-astrazeneca-to-progress-cytofab-into-phase-iib-study\/","name":"BTG PLC: ASTRAZENECA TO PROGRESS CYTOFAB\u2122 INTO PHASE IIB STUDY - SERB Pharmaceuticals","isPartOf":{"@id":"https:\/\/serb.com\/nl\/#website"},"datePublished":"2009-07-29T00:00:00+00:00","dateModified":"2022-09-08T10:04:00+00:00","breadcrumb":{"@id":"https:\/\/serb.com\/nl\/news\/btg-plc-astrazeneca-to-progress-cytofab-into-phase-iib-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/serb.com\/nl\/news\/btg-plc-astrazeneca-to-progress-cytofab-into-phase-iib-study\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/serb.com\/nl\/news\/btg-plc-astrazeneca-to-progress-cytofab-into-phase-iib-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/serb.com\/"},{"@type":"ListItem","position":2,"name":"BTG PLC: ASTRAZENECA TO PROGRESS CYTOFAB\u2122 INTO PHASE IIB STUDY"}]},{"@type":"WebSite","@id":"https:\/\/serb.com\/nl\/#website","url":"https:\/\/serb.com\/nl\/","name":"SERB Pharmaceuticals","description":"SERB Pharmaceuticals","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/serb.com\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/serb.com\/nl\/wp-json\/wp\/v2\/news\/1250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/serb.com\/nl\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/serb.com\/nl\/wp-json\/wp\/v2\/types\/news"}],"wp:attachment":[{"href":"https:\/\/serb.com\/nl\/wp-json\/wp\/v2\/media?parent=1250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}